EGFR and breast carcinoma: PGRMC1 not only interacts with FDFT1, and SCD1 (stearoyl-CoA desaturase1), but also increases the expression of these lipid metabolizing enzymes, and activates key oncogenic signalling pathways, such as ERα expression and activation, and EGFR signalling, potentially mediating proliferation and progression of breast cancer cells [93].